<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535739</url>
  </required_header>
  <id_info>
    <org_study_id>17-184/1440</org_study_id>
    <nct_id>NCT04535739</nct_id>
  </id_info>
  <brief_title>PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study</brief_title>
  <official_title>A Prospective Randomized Controlled Study for Prophylactic Cranial Irradiation After Chemotherapy and Thoracic Radiation Therapy in Patients With Extensive-stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      prophylactic cranial irradiation （PCI）was verified to decrease the brain metastases rates and&#xD;
      improve the overall survival（OS）for patients with limited stage small cell lung cancer.We&#xD;
      hypothesis that patients with extensive-stage small cell lung cancer after chemotherapy and&#xD;
      thoracic radiation can also benefit from PCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with extensive-stage small cell lung cancer achieving CR or PR after chemotherapy&#xD;
      and thoracic radiation therapy were randomly divided into observation group and prophylactic&#xD;
      cranial irradiation (PCI) group to evaluate the effect of PCI on survival after radiation&#xD;
      therapy for thoracic lesions. To preliminarily analyze the clinical characteristics of&#xD;
      patients who would benefit from thoracic radiation therapy plus PCI. To explore the optimal&#xD;
      treatment modality after chemotherapy + thoracic radiation therapy in patients with&#xD;
      extensive-stage SCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>rate of patients survival in 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>the rate of patients survival from the treatment to death or progress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain metastases rates</measure>
    <time_frame>2 year</time_frame>
    <description>Cumulative incidence of brain metastases over 2 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect</measure>
    <time_frame>2 year</time_frame>
    <description>HLVT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PCI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>prophylactic cranial irradiation</intervention_name>
    <description>25Gy/2.5Gy/10f were given for PCI patients</description>
    <arm_group_label>PCI group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years old,KPS≥70&#xD;
&#xD;
          -  Pathological or cytological diagnosis of stage IV small cell lung cancer (by using&#xD;
             AJCC 7th edition staging criteria);&#xD;
&#xD;
          -  1-3 extra-cranial metastatic organs before chemotherapy; 4-6 cycles of CE or EP ；&#xD;
&#xD;
          -  CR or PR after chemotherapy；&#xD;
&#xD;
          -  no grade ≥II side effects;&#xD;
&#xD;
          -  the estimated overall survival time ≥ 3 months;&#xD;
&#xD;
          -  no serious medical disease or major organ dysfunction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with brain or nervous system metastases;&#xD;
&#xD;
          -  Presence of high grade radiation comorbidities;&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>zongmei zhou, master</last_name>
    <phone>86 13801389769</phone>
    <email>zhouzongmei2013@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lei deng, dr</last_name>
    <phone>86 13683377570</phone>
    <email>dengleipumc@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zongmei zhou, master</last_name>
      <phone>86 13801389769</phone>
      <email>zhouzongmei2013@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zongmei Zhou</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>Brain Metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

